In contrast, pretreatment with VT or the Epac1 inhibitor ESI-09 significantly suppressed the expression of Epac1 and Rap1, reduced myocardial infarction, and alleviated left ventricular and mitochondrial dysfunction. Here, RAPGEF3 is linked to myocardial infarction.